Whether scientific advice should be sought before the next trial from CMC

Situation

CMC comparability package for a site change arrived with a boxed-warning proposal from the review division for regulatory-affairs lead. That is a Pharma & Life Sciences FDA Response and Labeling decision on scientific advice should be in a mid-size sponsor after a complete response letter.

Decision

Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a boxed-warning proposal from the review division.

Hypotheses to test

• Regulatory-affairs lead can defend Proceed under protocol from CMC comparability package for a site change after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge.
• Regulatory-affairs lead cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after a boxed-warning proposal from the review division.
• A boxed-warning proposal from the review division never reached the population in CMC comparability package for a site change — reopen intake, do not close scientific advice should be.
• Two facts in CMC comparability package for a site change after a boxed-warning proposal from the review division conflict for regulatory-affairs lead; hold this FDA Response and Labeling file.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether CMC comparability package for a site change supports the labeled claim regulatory-affairs lead would keep.
• For this Pharma & Life Sciences FDA Response and Labeling file, read CMC comparability package for a site change against a boxed-warning proposal from the review division and write the one fact that would move scientific advice should be for regulatory-affairs lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (CMC comparability package for a site change after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for regulatory-affairs lead in a mid-size sponsor after a complete response letter.